The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model

Journal of Immunology

Volumn 179, Issue 8, 2007, Pages 4979-4987

  Sharabi, Amir ^a   Luger, Dror ^a   Ben David, Hava ^a   Dayan, Molly ^a   Zinger, Heidey ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CASPASE 3; CASPASE 8; EDRATIDE; GAMMA INTERFERON; INTERLEUKIN 10; PROTEIN BCL XL; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CDR1 PROTEIN, MOUSE; NERVE PROTEIN; PEPTIDE; PROTEIN BCL X;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; IMMUNE COMPLEX DEPOSITION; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CASPASE 3; CASPASE 8; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PEPTIDES; UP-REGULATION;

EID: 38449119975     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.8.4979     Document Type: Article

References (41)

1. Nagy, G., A. Koncz, and A. Perl. 2005. T- and B-cell abnormalities in systemic lupus erythematosus. Crit. Rev. Immunol. 25: 123-140.
2. Tsokos, G. C., M. P. Nambiar, K. Tenbrock, and Y. T. Juang. 2003. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol. 24: 259-263.
3. Hahn, B. H. 2002. An overview of the pathogenesis of systemic lupus erythematosus. In Dubios' Lupus Erythematosus. D. Wallace and B. H. Hahn, eds. Lippincott Williams & Wilkins, Philadelphia, pp. 87-92.
4. Theofilopoulos, A. N. 1992. Murine models of lupus. In Systemic Lupus Erythematosus. R. G. Lahita, ed. Churchill Livingston, New York, p. 121.
5. Mendlovic, S., S. Brocke, Y. Shoenfeld, M. Ben-Bassat, A. Meshorer, R. Bakimer, and E. Mozes. 1988. Induction of a systemic lupus erythematosuslike disease in mice by a common human anti-DNA idiotype. Proc. Natl. Acad. Sci. USA 85: 2260-2264.
6. Waisman, A., S. Mendlovic, P. J. Ruiz, H. Zinger, A. Meshorer, and E. Mozes. 1993. The role of the 16/6 idiotype network in the induction and manifestations of systemic lupus erythematosus. Int. Immunol. 5: 1293-1300.
7. Manderson, A. P., M. Botto, and M. J. Walport. 2004. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 22: 431-456.
8. Paust, S., and H. Cantor. 2005. Regulatory T cells and autoimmune disease. Immunol. Rev. 204: 195-207.
9. Waisman, A., P. J. Ruiz, E. Israeli, E. Eilat, S. Konen-Waisman, H. Zinger, M. Dayan, and E. Mozes. 1997. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Natl. Acad. Sci. USA 94: 4620-4625.
10. Luger, D., M. Dayan, H. Zinger, J. P. Liu, and E. Mozes. 2004. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol. 24: 579-590.
11. + cells and TGF-β. Proc. Natl. Acad. Sci. USA 103: 8810-8815.
12. Sharabi, A., H. Azulai, Z. M. Sthoeger, and E. Mozes. 2007. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 121: 248-257.
13. 1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin. Immunol. 117: 262-270.
14. Sharabi, A., A. Haviv, H. Zinger, M. Dayan, and E. Mozes. 2006. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin. Immunol. 119: 146-155.
15. Waisman, A., Y. Shoenfeld, M. Blank, P. J. Ruiz, and E. Mozes. 1995. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int. Immunol. 7: 689-696.
16. Blanchard, H., M. Donepudi, M. Tschopp, L. Kodandapani, J. C. Wu, and G. M. Grutter. 2000. Caspase-8 specificity probed at subsite S(4): crystal structure of the caspase-8-Z-DEVD-cho complex. J. Mol. Biol. 302: 9-16.
17. Rosen, A., and L. Casciola-Rosen. 2001. Clearing the way to mechanisms of autoimmunity. Nat. Med. 7: 664-665.
18. Mevorach, D., J. L. Zhou, X. Song, and K. B. Elkon. 1998. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J. Exp. Med. 188: 387-392.
19. Green, D. R., N. Droin, and M. Pinkoski. 2003. Activation-induced cell death in T cells. Immunol. Rev. 193: 70-81.
20. Chun, H. J., L. Zheng, M. Ahmad, J. Wang, C. K. Speirs, R. M. Siegel, J. K. Dale, J. Puck, J. Davis, C. G. Hall, et al. 2002. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419: 395-399.
21. Kennedy, N. J., T. Kataoka, J. Tschopp, and R. C. Budd. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190: 1891-1896.
22. Garcia-Calvo, M., E. P. Peterson, B. Leiting, R. Ruel, D. W. Nicholson, and N. A. Thornberry. 1998. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273: 32608-32613.
23. Blanchard, H., L. Kodandapani, P. R. Mittl, S. D. Marco, J. F. Krebs, J. C. Wu, K. J. Tomaselli, and M. G. Grutter. 1999. The three-dimensional structure of caspase-8: an initiator enzyme in apoptosis. Structure 7: 1125-1133.
24. Seery, J. P., V. Cattell, and F. M. Watt. 2001. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl- (β-o-methyl)-fluoromethylketone. J. Immunol. 167: 2452-2455.
25. Llorente, L., Y. Richaud-Patin, R. Fior, J. Alcocer-Varela, J. Wijdenes, B. M. Fourrier, P. Galanaud, and D. Emilie. 1994. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum. 37: 1647-1655.
26. Foster, M. H., B. Cizman, and M. P. Madaio. 1993. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab. Invest. 69: 494-507.
27. Riemekasten, G., and B. H. Hahn. 2005. Key autoantigens in SLE. Rheumatology 44: 975-982.
28. Mok, C. C., and C. S. Lau. 2003. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 56: 481-490.
29. Kuo, P., M. S. Bynoe, C. Wang, and B. Diamond. 1999. Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. Eur. J. Immunol. 29: 3168-3178.
30. Kovacs, B., S. N. Liossis, G. J. Dennis, and G. C. Tsokos. 1997. Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity 25: 213-221.
31. Ohashi, R., H. Kitamura, and N. Yamanaka. 2000. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. J. Am. Soc. Nephrol. 11: 47-56.
32. Schelling, J. R., and R. P. Cleveland. 1999. Involvement of Fas-dependent apoptosis in renal tubular epithelial cell deletion in chronic renal failure. Kidney Int. 56: 1313-1316.
33. 1 mice with monoclonal antibody against Fas ligand. J. Autoimmun. 14: 151-157.
34. Chinnaiyan, A. M., K. O'Rourke, B. R. Lane, and V. M. Dixit. 1997. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science 275: 1122-1126.
35. Strasser, A., S. Whittingham, D. L. Vaux, M. L. Bath, J. M. Adams, S. Cory, and A. W. Harris. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. USA 88: 8661-8665.
36. Pandiyan, P., D. Gartner, O. Soezeri, A. Radbruch, K. Schulze-Osthoff, and M. C. Brunner-Weinzierl. 2004. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J. Exp. Med. 199: 831-842.
37. L serve an anti-inflammatory function in endothelial cells through inhibition of NF-κB. J. Clin. Invest. 103: 543-553.
38. Sela, U., M. Dayan, R. Hershkovits, L. Cahalon, O. Lider, and E. Mozes. 2006. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur. J. Immunol. 36: 2971-2980.
39. - T cells to dexamethasone-induced cell death. Eur. J. Immunol. 34: 859-869.
40. + regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J. Immunol. 176: 4125-4132.
41. + T cell suppressors. J. Immunol. 175: 7728-7737.